[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
3. Tomas D, Zovak M, Cicek S, Sulentić P, Jukić Z, Kruslin B: Mucinous cystadenoma arising in an isolated ileal duplication cyst. J Gastrointest Cancer; 2007;38(2-4):127-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenoma arising in an isolated ileal duplication cyst.
  • INTRODUCTION: A 64-year-old woman with a 2-year history of bilateral breast carcinoma with axillary node metastasis and chemotherapy was admitted to our hospital due to tumor attached to the ileum, discovered during the routine control examination.
  • DISCUSSION: Computerized axial tomography showed oval cystic tumor in terminal ileum that measured 7 cm in the largest diameter and shared peritoneal coat with small intestine and was filled with dense fluid.
  • The surgical procedure was simple because cyst was attached to the antimesenteric side of the terminal ileum and did not communicate with the adjacent intestine.
  • Pathohistological examination showed mucinous cystadenoma with high-grade epithelial dysplasia in the isolated ileal duplication cyst.
  • CONCLUSION: In conclusion, we report a unique case of mucinous cystadenoma arising in isolated ileal duplication cyst.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Cysts / pathology. Ileal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2003 Dec;38(12 ):1810-3 [14666474.001]
  • [Cites] Eur J Pediatr Surg. 2006 Apr;16(2):127-9 [16685621.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):4-25 [15626914.001]
  • [Cites] Surg Today. 2007;37(11):1013-7 [17952538.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):319-21 [15278075.001]
  • [Cites] J Pediatr Surg. 1999 Aug;34(8):1284-6 [10466615.001]
  • [Cites] Am J Surg. 2004 Feb;187(2):316-8 [14769328.001]
  • [Cites] J Pediatr Surg. 2007 May;42(5):E19-21 [17502171.001]
  • [Cites] Histopathology. 1988 May;12(5):527-32 [3397046.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):853-7 [17690906.001]
  • [Cites] Br J Surg. 1975 Apr;62(4):269-74 [1131505.001]
  • [Cites] World J Gastroenterol. 2005 Aug 14;11(30):4761-3 [16094726.001]
  • [Cites] Pediatr Surg Int. 2003 May;19(3):147-51 [12740704.001]
  • [Cites] Abdom Imaging. 2003 Jan-Feb;28(1):12-4 [12483377.001]
  • [Cites] Pediatr Surg Int. 2005 Oct;21(10 ):831-4 [16200403.001]
  • [Cites] J Pediatr Surg. 2004 Aug;39(8):e5-7 [15300555.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):93-4 [11869024.001]
  • [Cites] Arch Surg. 1994 Jun;129(6):659-61 [8204043.001]
  • [Cites] Australas Radiol. 2000 May;44(2):228-31 [10849993.001]
  • (PMID = 19089665.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Kanter J, Wilson DB, Strasberg S: Downsizing to resectability of a large solid and cystic papillary tumor of the pancreas by single-agent chemotherapy. J Pediatr Surg; 2009 Oct;44(10):e23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downsizing to resectability of a large solid and cystic papillary tumor of the pancreas by single-agent chemotherapy.
  • There are anecdotal reports of the use of neoadjuvant chemotherapy or radiation therapy for patients with unresectable tumors.
  • We report the case of a 14-year-old female with SCPT who was successfully downsized with gemcitabine before definitive surgical resection.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Cystadenoma, Papillary / pathology. Cystadenoma, Papillary / surgery. Deoxycytidine / analogs & derivatives. Neoadjuvant Therapy / methods. Pancreas / drug effects. Pancreas / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Biopsy / methods. Female. Humans. Pancreatectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19853735.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


5. Zuntová A, Sumerauer D, Teslík L, Kabícková E, Koutecký J: [Mixed germ cell tumours of the ovary in childhood and adolescence]. Cesk Patol; 2004 Jul;40(3):92-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mixed germ cell tumours of the ovary are rare malignant neoplasms containing combinations of two or more types of germ cell elements.
  • The aim of the study was to review biopsy examinations, medical records, treatment strategy, follow-up and outcome of all girls treated for mixed germ cell tumour of the ovary at the Department of Pediatric Oncology, University Hospital Motol during the period 1979-2002.
  • The clinical data on surgical treatment, chemotherapy and radiotherapy used and follow-up information were obtained in all girls.
  • All girls presented with unilateral tumour of the ovary and all underwent surgery as an initial treatment.
  • The original diagnosis of mixed histology was confirmed in all cases; in five cases the tumour contained three histologic components, in eleven cases the tumour consisted of two germ cell types.
  • All tumours contained elements of yolk sac tumour, followed by immature teratoma, embryonal carcinoma, dysgerminoma and mature teratoma.
  • At the time of diagnosis three patients had stage I disease, four patients stage II, seven stage III and two stage IV disease.
  • All patients were treated with chemotherapy after surgery, predominantly with platinum-based regimens (PVB, BEP).
  • Overall survival and event-free survival were 80% and 81.3% respectively (median follow-up time 7.6 years).
  • Three patients have died from the disease, two progressed on treatment (MAC), one girl relapsed three months after finishing therapy, no further therapy was administered.
  • Histology showed mixed serous and mucinous cystadenoma.
  • Microscopic examination should be extensive and careful to find out all types of malignant germ cell elements.
  • Platinum based chemotherapy is effective in the management of children and adolescents with mixed germ cell tumors of the ovary.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493415.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


6. Nicoletto MO, Dalla Palma M, Donach ME, Gusella M, Cappetta A, Shams M, Marchet A, Nardin M, Pintacuda G, Di Maggio A, Marchesi M, Carli P, Fiduccia P, Artioli G, Nitti D: Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer. Tumori; 2010 Nov-Dec;96(6):918-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
  • AIMS AND BACKGROUND: To assess feasibility and toxicity of intraperitoneal administration of cisplatin and paclitaxel, followed by intravenous chemotherapy in pretreated patients with suboptimal ovarian cancer (residuum >1 cm) or primary peritoneal tumor, and suffering from ascites and/or intestinal obstruction.
  • Intravenous chemotherapy was administrated 4 weeks following the last intraperitoneal paclitaxel instillation.
  • Ascites decreased in 11 patients: the median time to first need for paracentesis was 5 months, compared to a median baseline paracentesis of 4 weeks.
  • CONCLUSIONS: Intraperitoneal treatment was feasible, and enhanced response to the following intravenous chemotherapy was seen in these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm, Residual / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Ascites / etiology. Carcinoma, Papillary / drug therapy. Cystadenoma, Serous / drug therapy. Feasibility Studies. Female. Humans. Infusions, Intravenous. Infusions, Parenteral. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage. Platinum Compounds / administration & dosage. Retrospective Studies. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21388052.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Auner V, Sehouli J, Oskay-Oezcelik G, Horvat R, Speiser P, Zeillinger R: ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol; 2010 May;117(2):198-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABC transporter gene expression in benign and malignant ovarian tissue.
  • OBJECTIVE: ATP-binding Cassette (ABC) transporters are thought to cause multiple drug resistance (MDR) in various carcinomas.
  • Gene expression data from individual transporters in ovarian cancer tissue is contradictory and also scarce for some of them.
  • RNA levels of a panel of ABC transporters were collected and analyzed to get a more detailed overview which transporters are of importance in resistance to chemotherapeutic agents in ovarian carcinoma.
  • METHODS: Real-time PCR was used to determine RNA expression levels of 9 ABC transporters in 50 benign tissue samples and 50 recurrent ovarian cancer samples.
  • RESULTS: Gene expression of four transporters (ABCC1, ABCC2, ABCC3, and ABCB3) was significantly elevated in recurrent cancer lesions compared to benign tissue.
  • A significant difference between primary and recurrent tumor tissue was found in all four genes.
  • CONCLUSIONS: Four of the examined ABC transporters are likely to play a role in the MDR of ovarian carcinoma.
  • Gene expression of these transporters seems only up regulated through chemotherapy.
  • The thesis that MDR in ovarian cancer is acquired through therapy itself and not present ab initio is supported by these findings.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenoma / genetics. Cystadenoma / metabolism. Cystadenoma / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Gene Expression. Humans. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. ROC Curve. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19922990.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0W860991D6 / Deoxycytidine; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Roma AA, Malpica A: Primary retroperitoneal mucinous tumors: a clinicopathologic study of 18 cases. Am J Surg Pathol; 2009 Apr;33(4):526-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PRMTs are divided into mucinous cystadenoma (MC), mucinous borderline tumors or tumors of low malignant potential (MLMP), and mucinous carcinomas (MCas).
  • The gross appearance was variable: unilocular cyst with a thin wall (4 cases), predominantly cystic with papillary areas or nodule(s) (8 cases), multiloculated cyst with or without nodules (1 case each), and predominantly solid with cystic areas (4 cases).
  • Histologically, there were 2 cases of MC, 7 of MLMP (7 cases; 3 of them with intraepithelial carcinoma and 1 with microinvasion), and 9 of MCas (9 cases, 5 of them associated with MLMP and 1 associated with MC).
  • Three of the MCas had areas of anaplastic or sarcomatoid carcinoma whereas 1 had an associated sarcoma.
  • Two patients with MCa and sarcoma or sarcomatoid carcinoma received chemotherapy.
  • Two patients died of disease at 5 and 9 months; both had MCa with anaplastic carcinoma or sarcoma.
  • PRMTs seem to be nonaggressive neoplasms, except in cases containing anaplastic carcinoma or sarcoma.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / secondary. Cystadenoma, Mucinous / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Keratins / analysis. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092632.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


9. Tannuri AC, Tannuri U, Gibelli NE, Romão RL: Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation. J Pediatr Surg; 2009 Nov;44(11):2083-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation.
  • After neoadjuvant chemotherapy, tumor resectability was evaluated by another CT scan.
  • RESULTS: Fifty-three children with hepatic tumors underwent surgical treatment, 47 patients underwent liver resections, and in 6 cases, liver transplantation was performed because the tumor was considered unresectable.
  • There were 31 cases of hepatoblastoma, with a 9.6% mortality rate.
  • Six children had benign tumors-4 mesenchymal hamartoma, 1 focal nodular hyperplasia, and a mucinous cystadenoma.
  • [MeSH-minor] Age Factors. Blood Loss, Surgical. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Follow-Up Studies. Hepatectomy / methods. Hepatoblastoma / mortality. Hepatoblastoma / surgery. Humans. Infant. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome


10. Stankovic Z, Djuricic S, Djukic M, Jovanovic D, Vasiljevic M: Epithelial ovarian tumors and CA125 in premenarchal girls. Eur J Gynaecol Oncol; 2006;27(6):597-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient age, clinical presentation, operative procedures, histologic type of tumor, treatment and outcome were obtained.
  • Histological findings revealed cystadenoma in four girls, one with a mucinous borderline tumor and one with undifferentiated carcinoma.
  • The premenarchal girl with undifferentiated carcinoma in Stage III died after six months in spite of chemotherapy.
  • CA125 is a tumor marker with low sensitivity and specificity for detection of epithelial ovarian malignancy in this age group.
  • [MeSH-major] CA-125 Antigen / blood. Carcinoma / blood. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenoma, Serous / diagnosis. Ovarian Neoplasms / blood
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / blood. Child. Female. Humans. Menarche. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290590.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


11. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, Amunni G, Villanucci A, Garbini F, Baroni G, Taddei GL: Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol; 2005 Apr;16(4):590-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma.
  • BACKGROUND: Significant progress has been made in understanding the molecular biology of ovarian carcinoma.
  • RESULTS: Gamma/delta T cells are statistically correlated with a brief disease-free interval (P=0.036).
  • CD3 positive tumour-infiltrating T cells are correlated with a brief disease-free interval and with survival (P=0.004 and P=0.0001, respectively).
  • CD3 positive tumour-infiltrating T cells are associated with clinical responsiveness to chemotherapy (P=0.003).
  • CONCLUSIONS: Further studies are required to better understand the role of gamma/delta T cells in ovarian carcinoma, yet these data underline the importance of host immune response to cancer and the need to better study immune mechanisms to modulate the therapeutic treatment of cancer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699022.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


12. Lopez JM, Malpica A, Deavers MT, Ayala AG: Ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary. Ann Diagn Pathol; 2003 Oct;7(5):300-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary.
  • The clinicopathologic and immunohistochemical findings of an unusual case of ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary are reported.
  • Microscopic examination revealed that the tumor had a yolk sac component associated with an endometrioid carcinoma, grade I, and a mucinous cystadenoma.
  • Immunoperoxidase studies showed that the yolk sac component stained diffusely with a cytokeratin cocktail and was focally positive for alpha-fetoprotein.
  • In contrast, the endometrioid carcinoma stained positive for keratin 7 in addition to the cytokeratin cocktail, but was negative for alpha-fetoprotein.
  • After surgery, the patient received three cycles of chemotherapy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenoma, Mucinous / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasms, Multiple Primary. Postmenopause

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14571433.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 17
  •  go-up   go-down


13. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol; 2005 Nov;99(2):267-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: When ovarian carcinoma is diagnosed in stage I, up to 90% of patients can be cured with surgery and currently available chemotherapy.
  • Serum tumor markers that can be detected in ovarian cancers that lack CA125 expression might improve the sensitivity for early detection.
  • Tissue expression of CA125 was compared to serum CA125 levels.
  • Using immunoperoxidase staining of tissue arrays, we have assessed expression of 10 potential serum tumor markers in the 65 epithelial ovarian cancers with little or no CA125 expression and in ovarian cystadenomas, tumors of low malignant potential, normal ovaries, and 16 other normal tissues.
  • When reactivity with normal tissues was considered, however, MES and HE4 showed the greatest specificity.
  • CONCLUSIONS: At the level of tissue expression, each of 10 potential serum markers could be detected in 29-100% of ovarian cancers that had low or absent expression of CA125.
  • [MeSH-minor] Antigens / biosynthesis. Antigens / blood. Antigens, Neoplasm / biosynthesis. Antigens, Neoplasm / blood. CA-19-9 Antigen / biosynthesis. CA-19-9 Antigen / blood. Claudin-3. Cystadenoma / blood. Cystadenoma / metabolism. Epididymal Secretory Proteins / biosynthesis. Epididymal Secretory Proteins / metabolism. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. GPI-Linked Proteins. Glycoproteins / biosynthesis. Glycoproteins / blood. Humans. Immunohistochemistry. Kallikreins / biosynthesis. Kallikreins / blood. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / blood. Membrane Proteins / biosynthesis. Membrane Proteins / blood. Middle Aged. Mucin-1. Mucins / biosynthesis. Mucins / blood. Neoplasm Staging. Osteopontin. Sialoglycoproteins / biosynthesis. Sialoglycoproteins / blood. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / blood. beta-Defensins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061277.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA64602; United States / NCI NIH HHS / CA / CA80957
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / CLDN3 protein, human; 0 / Claudin-3; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Mucin-1; 0 / Mucins; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / Vascular Endothelial Growth Factor A; 0 / beta-Defensins; 0 / mesothelin; 106441-73-0 / Osteopontin; EC 3.4.21.- / KLK10 protein, human; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


14. Denkert C, Schmitt WD, Berger S, Reles A, Pest S, Siegert A, Lichtenegger W, Dietel M, Hauptmann S: Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer; 2002 Dec 10;102(5):507-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.
  • We investigated expression of MKP-1 in 90 cases of primary ovarian tumors, 11 normal ovaries as well as 4 ovarian carcinoma cell lines.
  • Immunohistochemical expression of MKP-1 protein was reduced in tissue from LMP tumors and invasive ovarian carcinomas compared to normal ovaries and cystadenomas.
  • We investigated expression and regulation of MKP-1 mRNA by Northern Blot in vitro using 4 ovarian carcinoma cell lines (SKOV-3, OVCAR-3, CAOV-3, OAW-42).
  • In OVCAR-3 cells MKP-1 mRNA levels were strongly inducible upon treatment of cells with cisplatin.
  • Expression of MKP-1 may be associated with shorter progression-free survival times.
  • Further studies are needed to determine whether MKP-1 expression is a clinically useful marker to estimate patient prognosis as well as the response to chemotherapy.
  • [MeSH-major] Carcinoma / enzymology. Cell Cycle Proteins. Immediate-Early Proteins / metabolism. Ovarian Neoplasms / enzymology. Phosphoprotein Phosphatases. Protein Tyrosine Phosphatases / metabolism
  • [MeSH-minor] Cisplatin / pharmacology. Cystadenoma / enzymology. Dual Specificity Phosphatase 1. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ovary / enzymology. Protein Phosphatase 1. RNA, Messenger / biosynthesis. Retrospective Studies. Survival Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12432554.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Immediate-Early Proteins; 0 / RNA, Messenger; EC 3.1.3.16 / Phosphoprotein Phosphatases; EC 3.1.3.16 / Protein Phosphatase 1; EC 3.1.3.48 / DUSP1 protein, human; EC 3.1.3.48 / Dual Specificity Phosphatase 1; EC 3.1.3.48 / Protein Tyrosine Phosphatases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Daponte A, Kostopoulou E, Papandreou CN, Chiotoglou I, Voutsadakis I, Vanakara P, Minas M, Nakou M, Kallitsaris A, Kollia P, Koukoulis G, Messinis IE: Retinoid receptor alpha and Beta expression in serous ovarian tumors. Oncology; 2007;73(1-2):81-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of retinoid acid receptors alpha (RARalpha) and beta (RARbeta) and estrogen receptor alpha (ERalpha) was assessed by immunohistochemistry and Western blotting in normal ovaries, serous cystadenoma (n = 20), serous borderline (n = 14), and serous ovarian cancer (n = 47) and was correlated in cancer cases with stage, grade, progress-free survival (PFS), and survival.
  • In stage III, G3 serous carcinoma, increased RARalpha expression was an independent prognostic factor associated with lower chemoresponse to first-line chemotherapy (taxol and carboplatin) and shorter PFS (p < 0.002).RARbeta and ERalpha expression did not correlate with RARalpha tumor characteristics or PFS and survival.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenocarcinoma, Serous / chemistry. Cystadenoma, Serous / chemistry. Estrogen Receptor alpha / analysis. Ovarian Neoplasms / chemistry. Receptors, Retinoic Acid / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blotting, Western. CA-125 Antigen / blood. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Radiography, Abdominal. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • figshare. supplemental materials - Supporting Data and Materials for the article .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • [ErratumIn] Oncology. 2010;78(2):124. Papandreou, C N [added]; Voutsadakis, I [added]
  • (PMID = 18334854.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Estrogen Receptor alpha; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta
  •  go-up   go-down


16. Das G, Bhuyan C, Das BK, Sharma JD, Saikia BJ, Purkystha J: Spleen-preserving distal pancreatectomy following neoadjuvant chemotherapy for papillary solid and cystic neoplasm of pancreas. Indian J Gastroenterol; 2004 Sep-Oct;23(5):188-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spleen-preserving distal pancreatectomy following neoadjuvant chemotherapy for papillary solid and cystic neoplasm of pancreas.
  • The tumor regressed with six cycles of gemcitabine and cisplantin-based neoadjuvant chemotherapy; spleen-preserving distal pancreatectomy was then done.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Papillary / surgery. Cystadenoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Adolescent. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Neoadjuvant Therapy. Risk Assessment. Spleen. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Spleen neoplasm.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15599007.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


17. Bondiau PY, Largillier R, Foa C, Rasendrarijao D, Frenay M, Gérard JP: [Treatment of brain metastasis from ovarian cancer]. Cancer Radiother; 2003 Jun;7(3):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of brain metastasis from ovarian cancer].
  • [Transliterated title] Traitement des métastases cérébrales du cancer de l'ovaire.
  • Systemic metastases from ovarian carcinoma are frequent, but they seldom affect the central nervous system.
  • We present here the case of a patient treated for an ovarian cancer by surgery and chemotherapy.
  • Three months after the end of chemotherapy, the patient developed cerebral metastases from ovarian carcinoma (CMOC) treated by iterative surgery and and whole brain irradiation.
  • CMOC can occur during or after adjuvant chemotherapy and the best management strategies to better define determinants of survival for patients are not well known.
  • It appears that a better outcome of CMOC may be obtained by an aggressive treatment, if possible, including surgery, radiotherapy, and chemotherapy.
  • Taking into account the increase in the incidence of the CMOC and their early occurrence, some authors have proposed a prophylactic brain radiotherapy in patients who receive adjuvant chemotherapy.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Cystadenoma, Serous / secondary. Cystadenoma, Serous / therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / blood. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Female. France / epidemiology. Headache / etiology. Humans. Magnetic Resonance Imaging. Metrorrhagia / etiology. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12834774.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CA-125 Antigen; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, Smyth J, Gabra H: Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer; 2004 May 15;100(10):2148-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A review of clinicopathologic features and outcome in women with carcinosarcoma of the ovary (also known as malignant mixed mesodermal tumor [MMMT]) compared with a group of women with serous adenocarcinoma (SAC) of the ovary was conducted.
  • METHODS: Between 1984 and 2002, 1568 patients with epithelial ovarian carcinoma and 70 patients with ovarian carcinosarcoma underwent treatment at the Edinburgh Cancer Centre.
  • Baseline variables were recorded prospectively and response to chemotherapy and progression-free and cause-specific survival between the groups were compared.
  • The objective response rate to platinum-based chemotherapy was found to be significantly lower in patients with carcinosarcoma (25% vs. 60%; P = 0.02).
  • Achieving optimal debulking at the time of initial surgery was found to be a highly significant factor in patients with carcinosarcoma with regard to determining outcome (median survival of 14.8 months for patients with optimally debulked International Federation of Gynecology and Obstetrics Stage III disease vs. 3.1 months for patients with suboptimally/nondebulked Stage III disease; P < 0.001).
  • CONCLUSIONS: Ovarian carcinosarcoma is a distinct entity with a poor prognosis.
  • Patients with carcinosarcoma differ from those with SAC with regard to having an older mean age of onset, an inferior response to platinum-based chemotherapy, and worse progression-free and cause-specific survival.
  • The extent of benefit from chemotherapy is unclear.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / mortality. Cystadenoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139057.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Camatte S, Morice P, Atallah D, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Castaigne D: Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg; 2002 Sep;195(3):332-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Forty-two patients were treated for BOT with a procedure that included lymphadenectomy.
  • Thirty-two patients underwent systematic lymphadenectomy, five because of associated cancer (uterine cervix or corpus) and five because of bulky nodes discovered during the surgical procedure.
  • None of the patients with a mucinous tumor had nodal involvement.
  • One patient died of a complication of adjuvant therapy (leukemia after chemotherapy).
  • This procedure should be carried out in patients with serous tumor and enlarged lymph nodes.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Combined Modality Therapy. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / therapy. Cystadenoma, Serous / pathology. Cystadenoma, Serous / therapy. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / therapy. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229940.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Păun I, Mogoş D, Păun M, Teodorescu M, Florescu M, Tenovici M, Mogoş G: [Diseases mimicking advanced-stage epithelial ovarian cancer]. Chirurgia (Bucur); 2010 Jul-Aug;105(4):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Postoperatively, the final histopathologic diagnoses consisted of primary peritoneal carcinoma (one pacient), peritoneal tuberculosis (TB, one pacient) and hepatic cirrosis with an incidental benign adnexial mass (one pacient).
  • The differential diagnosis of the ovarian cancer and a tailored approach to treatment for each of these three pathologic entities will also be described in detail.
  • [MeSH-major] Carcinoma / diagnosis. Cystadenoma / diagnosis. Liver Cirrhosis / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Peritonitis, Tuberculous / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Antitubercular Agents / therapeutic use. Ascites / diagnosis. Diagnosis, Differential. Diagnostic Errors. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoplasm Staging. Ovariectomy. Treatment Outcome


21. Morabito A, Bevilacqua P, Vitale S, Fanelli M, Gattuso D, Gasparini G: Clinical management of a case of recurrent apocrine gland carcinoma of the scalp: efficacy of a chemotherapy schedule with methotrexate and bleomycin. Tumori; 2000 Nov-Dec;86(6):472-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical management of a case of recurrent apocrine gland carcinoma of the scalp: efficacy of a chemotherapy schedule with methotrexate and bleomycin.
  • Apocrine carcinoma of the skin is a rare tumor.
  • Wide surgical excision with complete removal of the neoplasm is the standard therapy and this appears to offer the best chance of cure.
  • Systemic chemotherapy has not proved to be effective in the treatment of this tumor.
  • We report on a 46-year-old woman with a recurrent apocrine carcinoma of the scalp that had previously been treated with surgery, radiotherapy and chemotherapy (Al-Saraff schedule).
  • The patient was responsive to a second-line systemic chemotherapy regimen consisting of a weekly combination of methotrexate and bleomycin, and achieved long-term progression-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apocrine Glands. Carcinoma / therapy. Neoplasm Recurrence, Local / therapy. Sweat Gland Neoplasms / therapy
  • [MeSH-minor] Cystadenoma / therapy. Female. Humans. Lymph Node Excision. Middle Aged. Neck Dissection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11218189.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gyorffy H, Tihanyi T, Gyökeres T, Zsirka-Klein A, Kádár P, Kaszás I, Kovács M: [Pancreas pseudocyst or metastasis?]. Orv Hetil; 2005 Oct 23;146(43):2223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesion did not improve and the second CT scan suggested a suspicion of pancreatic cystadenoma.
  • The testicular tumour measuring 9 x 9 x 5 mm in diameter was diagnosed as embryonal carcinoma.
  • Later on the patient underwent chemotherapy.
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323569.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


23. Bing Z, Adegboyega PA: Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors. Appl Immunohistochem Mol Morphol; 2005 Mar;13(1):104-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors.
  • The authors report the first case of ovarian mucinous adenocarcinoma with metastasis from a synchronous small cell neuroendocrine carcinoma of the lung.
  • Bronchial brushing as well as transbronchial fine-needle aspiration was diagnostic of small cell carcinoma.
  • The patient received 3 cycles of chemotherapy with carboplatin and subsequently underwent a supracervical hysterectomy and bilateral salpingo-oophorectomy.
  • Microscopic examination disclosed a mucinous neoplasm with both mucinous cystadenoma and mucinous papillary adenocarcinoma components.
  • Immunohistochemistry showed that group of cells to be positive for thyroid transcription factor 1 and chromogranin, confirming them to be metastasis from the pulmonary small cell neuroendocrine carcinoma.

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722802.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 1.11.1.- / Peroxidases
  •  go-up   go-down


24. Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R: Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res; 2001 Nov;7(11):3457-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
  • PURPOSE: The purpose of this study was to analyze the expression of the high- and low-affinity nerve growth factor (NGF) receptors TrkA and p75 in effusions and in primary and metastatic tumors of serous ovarian carcinoma patients, as well as to evaluate their association with clinicopathological parameters and disease outcome.
  • RESULTS: TrkA protein membrane expression was detected in carcinoma cells in 30 of 77 (39%) effusions and 64 of 78 (82%) solid tumors.
  • Expression of p-TrkA in carcinoma cells was limited to 5 of 75 effusions.
  • TrkA and p75 showed no association with tumor grade, Fédération Internationale des Gynaecologistes et Obstetristes stage, chemotherapy status, the extent of residual disease, or survival (P > 0.05).
  • CONCLUSIONS: TrkA and p75 are both expressed in advanced-stage ovarian carcinoma, but whereas p75 expression is elevated in effusions, TrkA shows an opposite trend.
  • The similar expression of TrkA and p75 in carcinoma cells in pleural and peritoneal effusions provides further evidence for our hypothesis that there are few, if any, phenotypic differences between ovarian carcinoma cells at these two sites.
  • TrkA and p75 expression in effusions does not appear to be a predictor of disease outcome in advanced-stage serous ovarian carcinoma.
  • [MeSH-major] Ascitic Fluid / pathology. Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology. Pleural Effusion, Malignant / pathology. Receptor, trkA / genetics. Receptors, Nerve Growth Factor / genetics
  • [MeSH-minor] Animals. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Neoplasm Metastasis. Neoplasm Staging. Nerve Growth Factor / pharmacology. Phosphorylation / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, Nerve Growth Factor. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705863.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, Nerve Growth Factor; 0 / Receptors, Nerve Growth Factor; 9061-61-4 / Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA
  •  go-up   go-down


25. Ebert AD, Rosenow G, David M, Mechsner S, Magalov IS, Papadopoulos T: Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer. Gynecol Obstet Invest; 2008;66(3):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer.
  • CASE REPORT: A 54-year-old perimenopausal woman on tamoxifen (20 mg/day), gravida 0, with surgically treated invasive lobular breast cancer and extensive lobular carcinoma in situ (pT2 (m) pN0 (snl) pL0 G2 pTis (LCLIS) R0 M0 Ki-67 1%, ER+, PR+, Her-2-neu-negative) was referred for evaluation of a pelvic mass.
  • In the cystic ovary (right side), a serous cystadenoma close to a hemorrhagic corpus luteum (HCL) was diagnosed.
  • [MeSH-major] Breast Neoplasms / drug therapy. Cystadenoma, Serous / chemically induced. Endometriosis / chemically induced. Fallopian Tube Diseases / chemically induced. Leiomyoma / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / surgery. Corpus Luteum / drug effects. Corpus Luteum / pathology. Female. Hemorrhage / chemically induced. Humans. Immunohistochemistry. Middle Aged. Ovarian Diseases / chemically induced


26. Denschlag D, Ulrich U, Emons G: The diagnosis and treatment of endometrial cancer: progress and controversies. Dtsch Arztebl Int; 2010 Aug;108(34-35):571-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis and treatment of endometrial cancer: progress and controversies.
  • BACKGROUND: Endometrial carcinoma is the fourth most common type of cancer among women in Germany, with more than 11 000 newly diagnosed cases each year.
  • The additional or alternative administration of chemotherapy is a particular consideration for women at high risk, although the pertinent clinical trials to date have yielded conflicting evidence on this point.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / therapy. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / therapy. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / therapy. Evidence-Based Medicine. Neoplasms, Hormone-Dependent / diagnosis. Neoplasms, Hormone-Dependent / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemoradiotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dtsch Arztebl Int. 2010 May;107(20):353-9 [20539807.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1510-7 [9809732.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001040 [10796737.001]
  • [Cites] Lancet. 2010 Apr 3;375(9721):1165-72 [20188410.001]
  • [Cites] Lancet. 2010 Mar 6;375(9717):816-23 [20206777.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):788-92 [20065186.001]
  • [Cites] Int J Gynecol Cancer. 2009 Nov;19(8):1465 [19893425.001]
  • [Cites] Obstet Gynecol. 2009 Sep;114(3):523-9 [19701030.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3547-56 [19546404.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(2):CD000402 [19370558.001]
  • [Cites] Obstet Gynecol. 2009 Feb;113(2 Pt 1):319-25 [19155901.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):415-21 [18973934.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):137-46 [19070891.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16 [19033573.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2 Suppl):S101-4 [18804267.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):11-8 [18304622.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):255-61 [17624991.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):226-33 [17996926.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):282-8 [17662377.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):266-71 [16868539.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Curr Opin Obstet Gynecol. 2006 Jun;18(3):245-52 [16735822.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(2):CD003916 [17443533.001]
  • (PMID = 21904591.001).
  • [ISSN] 1866-0452
  • [Journal-full-title] Deutsches Ärzteblatt international
  • [ISO-abbreviation] Dtsch Arztebl Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3167060
  •  go-up   go-down


29. Hirasawa T: [Ovarian neuroendocrine carcinoma associated with mucinous carcinoma and teratoma]. Nihon Rinsho; 2004 May;62(5):973-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian neuroendocrine carcinoma associated with mucinous carcinoma and teratoma].
  • We experienced two rare case of ovarian neuroendocrine carcinoma (NEC); case 1, NEC associated with mucinous adenocarcinoma and dermoid cyst; case 2, NEC with mucinous cystadenoma.
  • The former patient was not treated with chemotherapeutic therapy for her own initiative and died of the tumor extent ten months after surgery.
  • The latter patient has taken an uneventful clinical course for ten years after surgery with chemotherapy.
  • The therapeutic protocols including chemotherapy and irradiation have not been established yet.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Neuroendocrine. Cystadenoma, Mucinous. Neoplasms, Multiple Primary. Ovarian Neoplasms

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15148829.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. McCluggage WG, Strand K, Abdulkadir A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer; 2002 Jan-Feb;12(1):62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metallothioneins (MTs) are a group of low-molecular-weight proteins that are overexpressed in a variety of human neoplasms and are related to differentiation and prognosis in some tumor types.
  • This study investigated immunohistochemically detectable metallothionein expression in benign and malignant ovarian surface epithelial tumors of serous, mucinous, and endometrioid types.
  • Whether high MT expression is an independent prognostic factor and increased expression indicates chemotherapy resistance in ovarian cancer, as has been previously suggested, should be determined by further studies.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Endometrioid / chemistry. Cystadenocarcinoma, Serous / chemistry. Cystadenoma, Mucinous / chemistry. Cystadenoma, Serous / chemistry. Metallothionein / analysis. Ovarian Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11860537.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  •  go-up   go-down


31. Skírnisdóttir I, Sorbe B: Body mass index as a prognostic factor in epithelial ovarian cancer and correlation with clinico-pathological factors. Acta Obstet Gynecol Scand; 2010;89(1):101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTING: Patients with EOC, who underwent primary surgery and postoperative chemotherapy in the Orebro Medical Region, Sweden, 1994-2003.
  • SAMPLE: A total of 446 patients with stage I-IV EOC, who underwent primary surgery and chemotherapy with information of values of height and weight at the start of chemotherapy were eligible.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / physiopathology. Chi-Square Distribution. Cystadenoma, Mucinous / mortality. Cystadenoma, Mucinous / physiopathology. Cystadenoma, Serous / mortality. Cystadenoma, Serous / physiopathology. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Multivariate Analysis. Overweight / epidemiology. Prognosis. Proportional Hazards Models. Retrospective Studies. Thinness


32. Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Köbel M, Dietel M, Hauptmann S: Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer; 2004 Feb 23;90(4):815-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
  • In this study, the expression of PLK1 and PLK3 was determined immunohistochemically in tissue specimen of normal ovaries (n=9), cystadenomas (n=17), borderline tumours (n=13) and ovarian carcinomas (n=77).
  • The overexpression of either isoenzyme had an impact on patient prognosis with shortened survival time for patients with tumours positive for PLK1 (P=0.02) and PLK3 (P=0.02), but only PLK1 expression remained a prognostic factor in multivariate survival analysis (P=0.03).
  • The results of this study, if interpreted in the context of recently published functional data, suggest that inhibition of PLKs might represent an interesting new targeted approach for chemotherapy of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / genetics. Carcinoma / pathology. Cell Cycle Proteins / biosynthesis. Cystadenoma / genetics. Cystadenoma / pathology. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Protein Kinases / biosynthesis. Protein-Serine-Threonine Kinases / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2000 May;436(5):403-12 [10881733.001]
  • [Cites] EMBO J. 1999 Oct 15;18(20):5528-39 [10523297.001]
  • [Cites] Pathol Res Pract. 2000;196(11):753-9 [11186170.001]
  • [Cites] Cancer Lett. 2001 Mar 10;164(1):41-9 [11166914.001]
  • [Cites] Cancer Lett. 2001 Aug 10;169(1):41-9 [11410324.001]
  • [Cites] J Cell Sci. 2001 Jul;114(Pt 13):2357-8 [11559744.001]
  • [Cites] J Neurooncol. 2001 May;53(1):1-11 [11678424.001]
  • [Cites] Int J Oncol. 2002 Jan;20(1):121-6 [11743651.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):423-9 [11906544.001]
  • [Cites] Mol Cell. 2002 Mar;9(3):515-25 [11931760.001]
  • [Cites] EMBO Rep. 2002 Apr;3(4):341-8 [11897663.001]
  • [Cites] Mol Cell Biol. 2002 May;22(10):3450-9 [11971976.001]
  • [Cites] J Natl Cancer Inst. 2002 Dec 18;94(24):1863-77 [12488480.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):69-80 [12527909.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15552-7 [11859075.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3162-71 [12082631.001]
  • [Cites] J Cutan Pathol. 2002 Jul;29(6):354-8 [12135466.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6633-40 [12242661.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8282-92 [12447691.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1912-34 [12471243.001]
  • [Cites] Nat Cell Biol. 2003 Feb;5(2):143-8 [12524548.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5789-94 [12732729.001]
  • [Cites] J Cell Sci. 1988 Jan;89 ( Pt 1):25-38 [3417791.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):543-9 [9053852.001]
  • [Cites] J Biol Chem. 1997 Nov 7;272(45):28646-51 [9353331.001]
  • [Cites] Mol Cell. 1998 Feb;1(3):371-80 [9660921.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):655-60 [9677325.001]
  • [Cites] Curr Opin Cell Biol. 1998 Dec;10(6):776-83 [9914175.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2794-7 [10383133.001]
  • [Cites] Int J Oncol. 1999 Oct;15(4):687-92 [10493949.001]
  • [Cites] Oncogene. 2000 Oct 5;19(42):4832-9 [11039900.001]
  • (PMID = 14970859.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Isoenzymes; 0 / Proto-Oncogene Proteins; EC 2.7.- / Protein Kinases; EC 2.7.1.- / PLK3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  • [Other-IDs] NLM/ PMC2410182
  •  go-up   go-down


33. Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B: Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol; 2010 Jun;41(6):794-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.
  • The objective of this study was to analyze the expression and clinical role of this pathway in serous ovarian carcinoma.
  • Higher phospho-AKT Thr308/pan-AKT ratio by Western blotting was associated with more advanced International Federation of Gynecology and Obstetrics stage (P = .018) and a trend for poor response to chemotherapy at first disease recurrence (P = .051).
  • The association between activated AKT and mammalian target of rapamycin expression and clinicopathologic parameters of aggressive disease, including shorter patient survival, provides further evidence regarding the central role of this signaling pathway in ovarian carcinoma.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cystadenoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Protein-Serine-Threonine Kinases / biosynthesis


34. Nagano K, Fukuda Y, Nakano I, Katano Y, Toyoda H, Ebata M, Morita K, Yokozaki S, Takeuchi M, Hayashi K, Hayakawa T: An autopsy case of multilocular cystic hepatocellular carcinoma without liver cirrhosis. Hepatogastroenterology; 2000 Sep-Oct;47(35):1419-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An autopsy case of multilocular cystic hepatocellular carcinoma without liver cirrhosis.
  • Although simple cysts, cystadenoma and cystadenocarcinoma of the liver have been well documented as hepatic cystic diseases, cystic hepatocellular carcinoma is a curious entity.
  • A part of the tumors contained cystic components, and were diagnosed as hepatocellular carcinoma by needle biopsy.
  • After giving informed consent, the patient was treated with several systemic chemotherapy using doxorubicin, fluorouracil, cyclophosphamide, cisplatin and oral anticancer agent UFT, a combination of uracil and tegafur, for almost 2 years.
  • During this time, the tumors enlarged gradually, and also underwent cyst formation, the patients then died of biliary sepsis.
  • Autopsy confirmed the diagnosis of multilocular cystic hepatocellular carcinoma without liver cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cysts / pathology. Doxorubicin / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Tegafur / therapeutic use. Uracil / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100365.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; 1-UFT protocol
  •  go-up   go-down


35. Iervolino P, Palmieri M, Rotondi M, D'Alessandro P, Iuliano R: [Borderline ovarian tumors. Retrospective analysis of 20 cases]. Minerva Ginecol; 2001 Feb;53(1 Suppl 1):97-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minimal requirements for conservative management were adequate staging and complete information about the therapeutic options.
  • Factors important in the choice of the treatment were, age, wish to preserve fertility, histologic type and grade, and the stage of the tumour.
  • Thirteen (65%) were with mucinous cystadenoma of borderline malignancy, 7 cases (35%) were of serous type.
  • Any patient were treated with chemotherapy after operation.
  • With a median follow up of two years, we observed no recurrence of carcinoma in women treated conservatively or in those treated more radically.
  • CONCLUSIONS: Conservative surgery remains a therapeutic option in selected patients with borderline ovarian tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11526732.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement